<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="31154">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02701127</url>
  </required_header>
  <id_info>
    <org_study_id>2016P000028</org_study_id>
    <nct_id>NCT02701127</nct_id>
  </id_info>
  <brief_title>Molecular Effects of Vitamin B3 (Niacinamide) in Acute Kidney Injury</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beth Israel Deaconess Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beth Israel Deaconess Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single center, randomized, single-blind, placebo-controlled study to evaluate the
      safety and biochemical effects of niacinamide on metabolic parameters of the kidney in
      patients undergoing cardiac surgery.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2016</start_date>
  <primary_completion_date type="Anticipated">April 2018</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Single Blind (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes from baseline in serum metabolite profile of niacinamide</measure>
    <time_frame>Baseline and days 1 through 4</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in urine metabolite profile of niacinamide</measure>
    <time_frame>Baseline and days 1 through 4</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Adverse events</measure>
    <time_frame>From enrollment through day 4, and at day 30</time_frame>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Acute Kidney Injury</condition>
  <arm_group>
    <arm_group_label>Niacinamide 1 gram</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral niacinamide, 1 gram daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Niacinamide 3 grams</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral niacinamide, 3 grams daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral placebo pill</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral niacinamide, 1 gram daily</intervention_name>
    <arm_group_label>Niacinamide 1 gram</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral niacinamide, 3 gram daily</intervention_name>
    <arm_group_label>Niacinamide 3 grams</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria

          1. All patients undergoing cardiac surgery with the use of cardiopulmonary bypass at
             high risk for acute kidney injury. A Cleveland score of 6 or more is used to define
             patients at high risk for acute kidney injury

          2. Age â‰¥ 18

          3. Signed informed consent

        Exclusion criteria

          1. Pre-existing acute kidney injury

          2. Kidney transplantation

          3. Off-pump heart surgery

          4. Pregnancy

          5. End stage renal disease

          6. Pregnancy (female subjects of childbearing potential must have a negative serum
             pregnancy test)

          7. Subjects with any kind of dependency on the investigator (e.g. any subject who is
             under direct supervision of the investigator/co-investigators or employed by the
             investigator/co-investigators) 8 Subjects held in an institution by legal or official
             order (e.g. subjects in jail, prison, juvenile offender facility, or treatment
             facility including those who are in hospitals, alcohol, and drug treatment facilities
             under court order, and individuals with psychiatric illnesses who have been committed
             involuntarily to an institution)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ali Poyan Mehr, M.D.</last_name>
    <phone>617-632-9880</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <lastchanged_date>August 17, 2016</lastchanged_date>
  <firstreceived_date>February 29, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beth Israel Deaconess Medical Center</investigator_affiliation>
    <investigator_full_name>Ali Poyan Mehr</investigator_full_name>
    <investigator_title>Instructor in Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Acute Kidney Injury</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Niacinamide</mesh_term>
    <mesh_term>Niacin</mesh_term>
    <mesh_term>Nicotinic Acids</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
